CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX – Get Free Report) saw a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 100,001 shares, a decline of 87.3% from the August 31st total of 788,894 shares. Based on an average trading volume of 10,440,031 shares, the short-interest ratio is presently 0.0 days.
CNBX Pharmaceuticals Trading Down 100.0%
CNBX Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.00.
About CNBX Pharmaceuticals
CNBX Pharmaceuticals Corp. is a biotechnology company focused on researching cannabinoid-based approaches to cancer treatment and personalized medicine. The company’s work centers on evaluating how cannabinoids and cannabis-derived compounds may affect cancer cells.
CNBX has developed a proprietary cannabinoid research and screening platform designed to test cannabis formulations against patient-derived cancer cells. The platform is intended to support the identification of potentially effective cannabinoid combinations and help researchers study individualized treatment options.
The company’s activities have primarily involved research and development rather than the sale of an established commercial pharmaceutical product.
Featured Stories
- Five stocks we like better than CNBX Pharmaceuticals
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for CNBX Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNBX Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
